Kailai Medicine-B (02105.HK) completed the issuance of 36 million shares for placement.

Capital Channel Finance APP News, Lai Kai Pharmaceuticals-B (02105.HK) has issued an announcement, all conditions for the placement have been met, and the placement was completed on September 17, 2025. According to the terms and conditions of the placement agreement, 36 million shares of placement shares have been successfully placed by the exclusive placement agent to no fewer than six underwriters at a placement price of HK$16.30 per share.